Gufic Biosciences Limited (BOM:509079)

Market Cap	37.53B
Revenue (ttm)	8.10B
Net Income (ttm)	819.76M
Shares Out	100.28M
EPS (ttm)	8.17
PE Ratio	45.79
Forward PE	n/a
Dividend	0.10 (0.03%)
Ex-Dividend Date	Sep 17, 2024

Volume	4,689
Average Volume	5,234
Open	372.10
Previous Close	371.45
Day's Range	372.10 - 383.15
52-Week Range	278.00 - 501.10
Beta	0.52
RSI	56.31
Earnings Date	May 29, 2025

About Gufic Biosciences

Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. It manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. The company also manufactures lyophilized injections, which include antibiotic, antifungal, cardiac medications, infertility treatments, antiviral solutions, and proton pump inhibitors (PPIs...

• Industry: Pharmaceutical Preparations
• Founded: 1970
• Employees: 1,491
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 509079

Financial Performance

In 2023, Gufic Biosciences's revenue was 8.07 billion, an increase of 16.80% compared to the previous year's 6.91 billion. Earnings were 861.36 million, an increase of 8.07%.